Cochrane Abstracts
Natalizumab for induction of remission in Crohn's disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Natalizumab for Induction of Remission in Crohn's Disease." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438028/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease.
Natalizumab for induction of remission in Crohn's disease. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438028/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease. Accessed December 30, 2024.
Natalizumab for induction of remission in Crohn's disease. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438028/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease
Natalizumab for Induction of Remission in Crohn's Disease [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 30]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438028/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Natalizumab for induction of remission in Crohn's disease
ID - 438028
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438028/all/Natalizumab_for_induction_of_remission_in_Crohn's_disease
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
